Skip to main content
Fig. 5 | Clinical Sarcoma Research

Fig. 5

From: Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry

Fig. 5

OS 3rd line, all other drugs group excludes patients that had regorafenib at a later time. Regorafenib improved overall survival by 11.9 months in 3rd line treatment compared to best supportive care with other TKI’s and excluding no treatment as best supportive care. Patients that had regorafenib in any treatment line were excluded from the all other drugs group. A high percentage of patients in regorafenib group were still alive at last follow-up (censored), suggesting an even greater benefit might be possible. Analysis limited to patients reporting progression in 2nd line

Back to article page

Clinical Sarcoma Research

ISSN: 2045-3329